Viyash Scientific Limited has appointed Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors following a postal ballot process that concluded on June 28, 2026. Additionally, the shareholders approved a one-time performance incentive for Mr. Rajaram Narayanan, Whole-time Director and CEO-Animal Health. The resolutions were passed with the requisite majority pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The postal ballot sought shareholder consent on three items of business. The appointments of Mr. Jain (DIN: 06917608) and Mr. Jayanthi (DIN: 10354445) were passed as ordinary resolutions. The approval for the performance incentive to Mr. Narayanan (DIN: 02977405) was passed as a special resolution. Nishant Darak & Associates, Practicing Company Secretary, acted as the scrutinizer for the e-voting process.

The remote e-voting commenced on May 30, 2026, and concluded on June 28, 2026. A total of 310,436,603 votes were polled, representing 71.06% of the total outstanding shares. The detailed voting results for each resolution are summarized below:

The special resolution regarding the performance incentive received 98.79% votes in favour, with 1.21% voting against it. Public institutions and non-institutions participated in the voting, with the promoter group voting entirely in favour of all resolutions. The scrutinizer's report confirmed that the voting process was conducted in a fair and transparent manner in accordance with the Companies Act, 2013 and the SEBI Listing Regulations.

Viyash Scientific Limited outlined its strategic roadmap to become a top 10 animal health player globally by 2030 during its Investor Day 2026 held on June 25, 2026, in Mumbai. The company presented its integrated pharmaceutical platform across animal and human health, backed by science and intellectual property, to stakeholders. Alongside its global ambitions, the company has set concrete financial milestones, targeting $1 billion in revenue and $250 million in EBITDA by 2032, with a return on capital employed (ROCE) of 25% and above.

Strategic Financial Targets

The company's financial roadmap includes a significant contribution from the companion animal segment, which is expected to generate between $150 million and $200 million. These targets reflect the company's intent to scale its integrated pharmaceutical platform and expand its presence across both animal and human health verticals. The following table summarises the key financial goals:

Company Background and Growth Journey

The presentation highlighted the company's evolution since its founding in February 2019 by Dr. Haribabu Bodepudi. Viyash Scientific expanded rapidly through the acquisitions of Vindhya Pharma, Vandana Life Sciences, Mylan's API and formulation units, Symed Labs, and Appco Pharma LLC. A strategic investment by the Carlyle Group further bolstered its position. The firm has filed over 175 patents and expanded its R&D team to more than 200 scientists.

Dr. Haribabu Bodepudi, the Group CEO, leads the organization with extensive experience in the pharmaceutical industry. Prior to his current role, he served as the CEO of Viyash Life Sciences and held leadership positions at Mylan, including CEO of Mylan India and Global COO. Under his leadership, the company has integrated operations and enhanced its global capabilities following the merger of Viyash Life Sciences with Sequent Scientific.

R&D Infrastructure

The company's R&D infrastructure is a key component of its growth strategy, with centres located in India, Spain, and Turkey. The facilities focus on scalable complex APIs, including high-potent and cytotoxic molecules, as well as formulation development for human and animal health. The table below outlines the R&D capabilities across locations:

Regulatory Compliance and Risk Disclosure

The company stated that its forward-looking statements regarding the 2030 and 2032 targets are based on current assumptions and involve risks, including economic developments, regulatory changes, and market competition. The presentation was submitted to the exchanges in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.